Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor type 4 (CCR4). It...

a few others are a second-line drug for cutaneous T-cell lymphoma. Mogamulizumab has been approved in Japan and the United States. In the Western population...

antagonist used as a treatment for pruritus in cutaneous T-cell lymphoma. Mogamulizumab is a CCR4 monoclonal antibody which has been shown to improve progression-free...

often expressed on leukemic cells in cutaneous T-cell lymphoma (CTCL). Mogamulizumab is a humanised monoclonal antibody targeted at CCR4 and is an investigational...

approval in Japan in April 2012 for a monoclonal antibody drug called mogamulizumab which was developed using the platform. Central nervous system medicines...

cyclic peptide histone deacetylase (HDAC) inhibitor (2018) Poteligeo (mogamulizumab-kpkc) Histone deacetylase (HDAC) inhibitors are shown to have antiproliferative...

CCR4 Agonists: CCL3 (MIP-1α) CCL5 (RANTES) CCL17 CCL22 Antibodies: Mogamulizumab (against CCR4) CCR5 Agonists: CCL3 (MIP-1α) CCL4 (MIP-1β) CCL5 (RANTES)...

potential use of a TBP-2 inducer as a novel therapeutic target. In 2021, mogamulizumab was approved for relapsed/refractor treatment of ATL in Japan. At a...

Ipilimumab Isatuximab Loncastuximab tesirine Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab...

romidepsin, belinostat, brentuximab vedotin, lenalidomide, alisertib, and mogamulizumab. These drugs are being further studied for their usefulness for refractory...